EGFR and lung adenocarcinoma: Both the EVIDENCE (38) and CONVINCE (41) studies demonstrated that icotinib considerably reduced DFS and serious adverse effects compared to chemotherapy for patients with EGFR-mutated lung adenocarcinoma.